Theravance Biopharma (NASDAQ:TBPH) Shares Gap Down After Analyst Downgrade

Theravance Biopharma, Inc. (NASDAQ:TBPH) shares gapped down prior to trading on Monday after JonesTrading downgraded the stock from a buy rating to a hold rating. The stock had previously closed at $17.63, but opened at $16.97. Theravance Biopharma shares last traded at $17.04, with a volume of 771,977 shares trading hands.

TBPH has been the subject of a number of other research reports. Weiss Ratings lowered Theravance Biopharma from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, May 27th. BTIG Research downgraded Theravance Biopharma from a “buy” rating to a “neutral” rating in a report on Monday. Wall Street Zen cut Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Zacks Research cut Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 8th. Finally, HC Wainwright raised their price target on Theravance Biopharma from $20.00 to $27.00 and gave the company a “buy” rating in a report on Monday, March 2nd. One analyst has rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $21.40.

Insider Activity

In other news, SVP Rhonda Farnum sold 13,314 shares of Theravance Biopharma stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $16.39, for a total value of $218,216.46. Following the completion of the sale, the senior vice president directly owned 232,457 shares in the company, valued at $3,809,970.23. The trade was a 5.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.65% of the stock is currently owned by insiders.

Key Headlines Impacting Theravance Biopharma

Here are the key news stories impacting Theravance Biopharma this week:

• Positive Sentiment: Theravance Biopharma agreed to be acquired by Zymeworks for $17.00 per share in cash, a transaction that could unlock value for shareholders if completed. Article link
• Positive Sentiment: The deal includes a CVR giving Theravance shareholders 80% of any future net proceeds from ampreloxetine monetization, providing additional upside beyond the cash payment. Article link
• Neutral Sentiment: Multiple shareholder-rights law firms have launched investigations into whether the sale process and $17.00 per-share price are fair to public shareholders, which could add headlines but does not change the announced terms. Article link
• Neutral Sentiment: JonesTrading downgraded Theravance Biopharma from buy to hold, reflecting a more cautious stance after the acquisition announcement. Article link
• Negative Sentiment: The market is also reacting to the fact that the company’s strategic review was triggered by the failure of ampreloxetine, which may have limited standalone growth prospects and helped push the company toward a sale. Article link

Institutional Investors Weigh In On Theravance Biopharma

Large investors have recently added to or reduced their stakes in the stock. Quarry LP purchased a new stake in Theravance Biopharma during the 3rd quarter valued at $26,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Theravance Biopharma by 26.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 515 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in shares of Theravance Biopharma by 107.4% in the third quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 1,411 shares during the period. CIBC Private Wealth Group LLC grew its holdings in shares of Theravance Biopharma by 20,269.6% in the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock worth $68,000 after acquiring an additional 4,662 shares during the period. Finally, Tower Research Capital LLC TRC increased its position in Theravance Biopharma by 18.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 781 shares during the last quarter. Institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Price Performance

The business has a 50-day moving average of $16.56 and a 200 day moving average of $17.29. The company has a market cap of $876.35 million, a PE ratio of 7.73 and a beta of 0.17.

Theravance Biopharma (NASDAQ:TBPH) last announced its earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter. The firm had revenue of $17.70 million during the quarter. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%. On average, equities analysts predict that Theravance Biopharma, Inc. will post 1.54 EPS for the current fiscal year.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.